TOP > 外国特許検索 > ANTI-HTLV-1 DRUG AND THERAPEUTIC AGENT FOR HTLV-1-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS (HAM/TSP)

ANTI-HTLV-1 DRUG AND THERAPEUTIC AGENT FOR HTLV-1-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS (HAM/TSP)

外国特許コード F180009367
整理番号 (1705-15P012,S2016-0957-N0)
掲載日 2018年4月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP028094
国際公開番号 WO 2018025923
国際出願日 平成29年8月2日(2017.8.2)
国際公開日 平成30年2月8日(2018.2.8)
優先権データ
  • 特願2016-152871 (2016.8.3) JP
発明の名称 (英語) ANTI-HTLV-1 DRUG AND THERAPEUTIC AGENT FOR HTLV-1-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS (HAM/TSP)
発明の概要(英語) Provided are a novel therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and a novel anti-HTLV-1 drug. The therapeutic agent and the anti-HTLV-1 drug comprise, as an active ingredient, a substance capable of inhibiting tyrosine kinase encoded by ABL1 gene.
従来技術、競合技術の概要(英語) BACKGROUND ART
T lymphocytes tropic viruses-human (hereinafter, HTLV-1) is 1, the genomic DNA of CD4 positive lymphocytes T is incorporated, between the body and individual infected with a retrovirus propagation. HTLV-1 tumor infected cells in adult T cell leukemia can be developed (ATL), the infected cells in the spinal cord HTLV-1 spastic paralysis and dysuria in infiltrating the spinal cord associated with interfering with the spinal disease HTLV-1 (HAM/TSP: HAM HTLV-1-associated myelopathy/tropical spastic paraparesis, may be referred to below) to develop. Further, HTLV-1 in infected cells infiltrating into the eye and uveitis andcorticosteroids (HU).
HTLV-1 above HAM will be due to one of the various diseases, HTLV-1 infected cells in the spinal cord can cause inflammation in the infiltrated except that the trigger, is unknown at development mechanism. Current, with respect to the HAM, and the establishment of a non-therapy to cure, the rate of disease progression in accordance with the magnitude of the inflammation, the treatment is performed to reduce inflammation. Strong inflammation if there is a high possibility to the disease, steroid therapy, interferon, alpha is selected for treatment such as injection therapy, to suppress the inflammation of the spinal cord is prevented from being broken. Specifically, anti-inflammatory agents can include corticosteroids (prednisolone: Predonisolone) oral administration, proviral to reduce the amount of a certain degree, the effect of improving the symptoms have been identified. However, in many cases, the treatment methods, completion of the jig and the like cannot be rebound by the problem of drug withdrawal. Further, the steroid diabetes chiryo method, and immunosuppression may be side effects such as osteoporosis.
As described above, due to HAM HTLV-1, therapeutic for the treatment and cure has been demanded. For example, to Patent Document 1, specifically a human anti-human CXCL10 CXCL10 antibody or antibody fragments, associated with the drugs for the treatment of spinal cord HTLV-1 has been disclosed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • KODAMA Daisuke
  • KUBOTA Ryuji
  • IZUMO Shuji
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
鹿児島TLOでは鹿児島大学、鹿屋体育大学から特許に関する技術移転を受託しています。
上記の特許・技術に興味を持たれた方はお問合せ下さい。

PAGE TOP

close
close
close
close
close
close